ArticleMedicine2022
Effects of low-FODMAP diet on irritable bowel symptoms in patients with quiescent inflammatory bowel disease: A protocol for a systematic review and meta-analysis.
Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- The efficacy of dietary therapies in modulating inflammatory biomarkers, clinical remission and quality of life in patients with inflammatory bowel disease: a network meta-analysis of 15 interventions.Frontiers in nutrition · 2025Pooled it
- Effectiveness of the low FODMAP diet in patients with irritable bowel syndrome and small intestine bacterial overgrowth syndrome.Frontiers in nutrition · 2026Article
- An umbrella review of meta-analyses on the low-FODMAP diet in IBS.Frontiers in nutrition · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is a chronic disease whose etiology is not yet fully understood, and their course is characterized by periods of exacerbation and remission. In quite a few cases, actual disease remission may also accompany with inflammatory bowel disease (IBS)-like symptoms such as abdominal pain, bloating, flatulence, and diarrhea, may greatly impact quality of life. An army of strong evidence to support the FODMAPs diet (LFD) compounds as an effective dietary approach to IBS treatment. However, there is no significant evidence showing the effectiveness of LFD in treating quiescent IBD and its side effects; this lack of evidence is also an important factor hindering its promotion in the treatment of IBD and its complications. Therefore, this systematic review and meta-analysis will evaluate the efficacy and safety of LFD in the treatment of quiescent IBD patients with IBS-like symptoms.
methodWe searched the following databases from their establishment until December 2021: PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP, and Wanfang databases. No restrictions regarding publication date or language were applied. Keywords such as "Crohn's disease," "ulcerative colitis," "inflammatory bowel disease," and "FODMAPs" have been combined for search. Ongoing and unpublished research in the Clinical Trials Registry Research will also be included. At the same time, we will manually search all reference lists from relevant systematic reviews for other eligible studies. The selected studies were randomized controlled clinical trials. We will meta-analyze the selected literature by Review Manager software (REVMAN v5.4 Cochrane Collaboration). Two researchers will independently review the research selection, data extraction, and research quality assessments. Finally, we will observe the outcome measures.
resultsThis study will provide evidence-based data for TFD treatment of IBD and provide new treatment options for future clinical applications. ETHICS AND DISSEMINATION: The protocol of the systematic review does not require ethical approval because it does not involve humans. This article will be published in peer-reviewed journals and presented at relevant conferences. REGISTRATION NUMBER: INPLASY202220060.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.